Creapharm Europe has established a U.S. subsidiary, Creapharm-MP5, Inc. Through its subsidiaries Creapharm and MP5, Creapharm Europe manufacturers cytotoxic and other high-potency drugs as well as clinical supply services. As part of the launch, Matthew Maupin has been appointed vice president of business development, North America. Mr. Maupin’s efforts will focus on promoting MP5’s services in the U.S. and Canada with particular focus on the oncology market. He will also promote Creapharm’s ...